Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

cgenetech.com.cn

Founded Year

2010

Stage

Series A - II | Alive

Total Raised

$29.61M

Last Raised

$14.5M | 3 yrs ago

About CGeneTech

CGeneTech is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads.

CGeneTech Headquarters Location

Suzhou, Jiangsu,

China

+86-512-62956962

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing CGeneTech

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CGeneTech is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

838 items

CGeneTech Patents

CGeneTech has filed 2 patents.

The 3 most popular patent topics include:

  • Amines
  • Chemokine receptors
  • Clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/24/2018

7/26/2022

Cytokines, Clusters of differentiation, Chemokine receptors, Rare diseases, Immunology

Grant

Application Date

9/24/2018

Grant Date

7/26/2022

Title

Related Topics

Cytokines, Clusters of differentiation, Chemokine receptors, Rare diseases, Immunology

Status

Grant

Latest CGeneTech News

Aug. 2 Financial Quick Takes: Rakuten Medical bags another $100M; plus CGeneTech, Zecen, Qyuns and more

Aug 2, 2019

Aug. 2 Financial Quick Takes: Rakuten Medical bags another $100M; plus CGeneTech, Zecen, Qyuns and more 4:30 PM Rakuten Medical raises another $100 million  Rakuten Medical Inc. (San Diego, Calif.) raised $100 million in a series C-1 round from existing investor Rakuten Inc. (Tokyo:4755), giving the Japanese internet giant a 22.6% stake. The biotech closed a $284 million series C round in December 2018, with Rakuten Chairman and CEO Hiroshi Mikitani leading the round. Mikitani is also CEO of Rakuten Medical, formerly known as Aspyrian Therapeutics Inc. The company's photoimmunotherapy, ASP-1929, is in Phase III testing for squamous cell carcinoma of the head and neck (SCCHN); it consists of cetuximab conjugated to IRDye 700DX, a chemical dye activated upon near-infrared light illumination, to induce cell death in cells expressing EGFR. RAPT delays IPO  A spokesperson for RAPT Therapeutics Inc. (South San Francisco, Calif.) told BioCentury the company has chosen to delay its IPO but declined to disclose why. The inflammatory disease company had proposed in July to sell 5 million shares at $14-$16. Hongtai backs Chinese companies CGeneTech, Zecen, Qyuns   Hongtai Capital led separate venture rounds for small molecule company CGeneTech Co. Ltd. (Suzhou, China), diagnostics play Jiangsu Zecen Biotechnology Co. Ltd. (Jiangsu, China) and autoimmune disease company Jiangsu Qyuns Bio-Pharmaceutical Co. Ltd. (Jiangsu, China). CGeneTech raised RMB130 million ($18.7 million) in an A+ round that also saw participation by ABC International. The financing will be used to support development of the company’s small molecule pipeline including lead candidate cetagliptin, a DPP-4 inhibitor in Phase I testing for diabetes. Jiangsu Zecen completed a RMB180 million ($25.9 million) series C round. WuXi Capital, Ningbo Ruiyun and other investors joined the round. The company markets chemiluminescence-based diagnostic equipment and reagents for various diseases including cancer, diabetes, hepatic fibrosis and infectious disease. Jiangsu Qyuns, which develops biosimilars and antibodies, raised "several hundred" million RMB in a series B round also backed by Hefu Ruitai and Triwise Capital. Its tocilizumab and ustekinumab biosimilars, QX003S and QX001S, are in Phase I trials for rheumatoid arthritis and psoriasis, respectively. Its most advanced antibody, QX002N, has received IND approval in China to treat ankylosing spondylitis; its target is undisclosed. Prellis raises $8.7M series A   Prellis Biologics Inc. (San Francisco, Calif.) raised $8.7 million in a series A round led by Khosla Ventures, bringing the total venture capital raised by the company since its founding in 2016 to $10.5 million. Seed investors True Ventures and Indie Bio joined the round. Prellis develops 3-D tissue scaffolds for R&D and organ transplantation. Targets: DPP-4 (CD26) - Dipeptidyl peptidase-4; EGFR (ErbB1; HER1) - Epidermal growth factor receptor User Sign in

  • When was CGeneTech founded?

    CGeneTech was founded in 2010.

  • Where is CGeneTech's headquarters?

    CGeneTech's headquarters is located at Suzhou.

  • What is CGeneTech's latest funding round?

    CGeneTech's latest funding round is Series A - II.

  • How much did CGeneTech raise?

    CGeneTech raised a total of $29.61M.

  • Who are the investors of CGeneTech?

    Investors of CGeneTech include Hongtai Capital Holdings, ABC International, Addor Capital, JiangSu QianRong Assets Management, Kington Capital and 5 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.